AKTS Aktis Oncology Inc.
Aktis Oncology Inc. (AKTS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $861.7K.
Where they traded
Last open-market purchase: January 12, 2026 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Herrmann Ken 2 fills | Director | Sell | 4,856 | $24.56 | $119.3K | 1,350 −78.2% of holding | |
| Herrmann Ken | Director | Sell | 3,065 | $25.21 | $77.3K | None left | |
| Czibere Akos 3 fills | Chief Medical Officer | Sell | 50,000 | $27.77 | $1.4M | 35,200 −58.7% of holding | |
| Ron-Bigger Shulamit 3 fills | Chief Operating Officer | Sell | 50,000 | $27.75 | $1.4M | 34,200 −59.4% of holding | |
| 6 fills | Buy | 5,282,776 | $18.00 | $95.1M | 10,260,064 | ||
| Kim Helen Susan 2 fills | Director | Buy | 835,000 | $18.00 | $15.0M | 5,671,825 | |
| Foley Todd | Director | Buy | 232,870 | $18.00 | $4.2M | 4,235,403 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.